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Allostery has come of age; the number, breadth and functional roles of documented
protein allostery cases are rising quickly. Since all dynamic proteins are potentially
allosteric and allostery plays crucial roles in all cellular pathways, sorting and classifying
allosteric mechanisms in proteins should be extremely useful in understanding and
predicting how the signals are regulated and transmitted through the dynamic
multi-molecular cellular organizations. Classification organizes the complex information
thereby unraveling relationships and patterns in molecular activation and repression. In
signaling, current classification schemes consider classes of molecules according to their
functions; for example, epinephrine and norepinephrine secreted by the central nervous
system are classified as neurotransmitters. Other schemes would account for epinephrine
when secreted by the adrenal medulla to be hormone-like. Yet, such classifications
account for the global function of the molecule; not for the molecular mechanism of
how the signal transmission initiates and how it is transmitted. Here we provide a unified
view of allostery and the first classification framework. We expect that a classification
scheme would assist in comprehension of allosteric mechanisms, in prediction of
signaling on the molecular level, in better comprehension of pathways and regulation of
the complex signals, in translating them to the cascading events, and in allosteric drug
design. We further provide a range of examples illustrating mechanisms in protein
allostery and their classification from the cellular functional standpoint.
Introduction
Allostery has been attracting increasing
attention. This is not surprising: allostery
is the key in regulation of cellular processes
and a vehicle through which the environ-
ment aﬀects function.1 All dynamic pro-
teins are potentially allosteric.2 Allostery
regulates cellular assemblies and pathways.
It is a universal phenomenon: a perturba-
tion by an eﬀector leads to a functional
change at the substrate binding site
through alteration of the shape and (or)
dynamics.3 Allosteric perturbation arises
from the binding of small and large mole-
cules; from changes in pH, temperature,
ionic strength, or concentration; and
from covalent modiﬁcations such as
tethering,4 glycosylation, phosphorylation
and ubiquination.5–7 Allostery is a
cooperative event,8 positive or negative;
up- or down-regulating protein functions.
Further, allosteric behavior was observed
also in eglin c, a small globular protein,
which is presumably a non-allosteric
protein.9 Yet, despite this intense interest,
how signals initiating at the perturbation
site transmit through the residue network
is still an open and debated question.
Nonetheless, there is a general agreement
that the energetic strain at the perturbation
site dissipates, leading to a functional
change in the substrate binding site.
The broad recognition of allosteric
eﬀects often does not translate into con-
sideration in practical applications. One
example is drug design: traditional
strategy seeks to block enzyme activity
by designing inhibitors snugly ﬁtting the
enzyme binding site. Following this
rationale, to block a certain cellular pro-
cess, a strategy of choice considers a high
aﬃnity inhibitor mimicking the natural
binding epitope. Yet, in practice, such
rationale can enhance function rather
than repress it. HIV-1 gp120 provides a
striking example:10 the binding of gp120
to CD4 precedes gp120 binding to a
co-receptor and viral entry into the cell.
Unexpectedly, a CD4 mimetic designed
to interrupt the cascading pathway led to
the opposite eﬀect: rather than repres-
sing, it enhanced gp120 co-receptor
binding, mimicking the CD4 allosteric
consequences. Subsequent design
targeted CD4 binding and its allosteric
eﬀects obtaining peptide conjugates that
function as dual receptor site antagonists
of HIV-1 gp120.
The increasing number of reports on
allosteric eﬀects in a broad range of
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proteins, functions, assembly sizes and
environments argues for the usefulness
of classiﬁcation of allosteric mechanisms.
Here we describe allosteric mechanisms
within the framework of cellular path-
ways and transmission of information,11–15
and provide a classiﬁcation scheme
with some examples from a broad range
of processes taking place in the cell
illustrating the functional eﬀects. Our
description initiates by uniting the old
and new mechanistic views of allostery;
this traditional division is a matter
of deﬁnition.
Allostery: the old and the new
views
(i) The old view
The classical allosteric models (Monod–
Wyman–Changeux: MWC16 and
Koshland–Ne´methy–Filmer: KNF17)
described allostery as a binding event at
one site aﬀecting the activity at another
via a conformational change. The MWC
model described the transition as a con-
certed action between two co-existing,
discrete states (R and T); the KNFmodel
described it as a sequential, induced con-
formational change by the binding event
at the ﬁrst site. The classical dogma had
two components: ﬁrst, there are two dis-
tinct R and T conformations; in the
absence of a ligand they exist in a ratio
governed by an equilibrium constant;
and second, allostery involves a change
of shape. This view perpetuated over de-
cades. It was fed by static crystallographic
snapshots of allosterically-regulated
proteins showing a clear diﬀerence in
the shape of the substrate binding site
between the active/inactive species. And,
the change of shape was observed be-
tween eﬀector-bound and free states.
Hence, it was an all-or-none view: either
the On conformation is present or the
Oﬀ. Although not directly stated by the
classical view, the two-state model
implied that signal propagation from
the eﬀector to the substrate binding site
proceeded along a single, speciﬁc, well-
deﬁned path. Distinct residues involved
in the allosteric signal transmission that
were identiﬁed by experiment were inter-
preted in this light.18 The so-called old
view can then be described by three
characteristics: (i) there are only two
states; (ii) there is a conformational
change in the substrate binding site;
and (iii) the allosteric signal is trans-
mitted via a single pathway.
(ii) The new view
Current evidence indicates that the native
state is a conformational ensemble, and
that allosteric perturbation involves a
shift of pre-existing conformations; some
already with altered binding site
shapes.2,19–21 The dissipating strain22
drives the shift, increasing the pre-existing
(though undetected) functional state
population.21 Moreover, recent experi-
mental data3,23 conﬁrms early predic-
tion:24 while visual inspection of the
active/inactive states may not reveal
any diﬀerence in the substrate binding
site shape, allosteric eﬀects can be there,
reﬂected purely in changes in dynamics.
Allostery without a change in shape was
not foreseen by the old view.
Taken together, the new view expands
the deﬁnition of allostery: (i) it empha-
sizes that rather than only two con-
formational states, proteins exist in
ensembles; (ii) it recognizes that allostery
is a thermodynamic phenomenon; thus,
can be governed by enthalpy, enthalpy
and entropy or entropy. There may or
may not be a backbone conformational
change. Hence, the absence of a con-
formational change in the substrate
binding site does not imply that allostery
is not at play; and ﬁnally, (iii) the
existence of multiple conformational
and dynamic states implies multiple
pathways through which the strain
energy is released from the allosteric site
following a perturbation event.
Allostery: the unified view
We cast the three attributes of the old
view in the terminology of the new view,
illustrating that the two can be uniﬁed by
deﬁnition. A uniﬁed view facilitates a
description of allosteric mechanisms
and their classiﬁcation.
(i) Protein states: two versus
multiple conformational states
Fundamental to the old view is the pre-
sence of two (On/Oﬀ) states. The uniﬁed
view interprets the allosteric switch as
simply referring to the diﬀerence between
an observable and non-observable
functional eﬀect, rather than all-or-none
conformational states.3,25–27
(ii) There may or may not be a
conformational change
The hallmark of the old view was a
conformational change at the binding
site induced by the allosteric perturba-
tion event; in the uniﬁed view, this is one
of the scenarios.
(iii) Pathways: single well-defined
versus multiple
Single well-defined communica-
tion pathways. A sequence-based
statistical method mapped the residue
interaction network, obtaining thermo-
dynamic couplings between spatially
adjacent residues for e.g. PDZ domains,
GPCRs, chymotrypsin and hemo-
globin.18,28,29 The conformational change
was proposed to propagate through a
distinct pathway involving these
spatially-contacting residues. Milli-
second (ms) dynamics mapped a signal
transmission network of a peptide bind-
ing to the PDZ domain,30 correlating
with the previously found dynamic31
and the thermodynamic coupling.28,32
More recently, pathways responsible for
the transmission of the allosteric changes
in the PDZ domain have been further
described in detail.33 In another study,
applying higher order double-mutant
cycles thermodynamic analysis,34–37 a
hierarchical allosteric coupling organiza-
tion was observed between distal
voltage-activated potassium channel
regions.38 Thus, two points emerge: first,
energy transfer in the trajectory is
cooperative; and second, the trajectory
boundary is well-defined, arguing for
specific communication paths where a
pathway outlines an energetic connec-
tivity. A well-defined pathway scenario
can also be cast into the unified view. We
note, however, that not all of the dynami-
cally coupled residues28,31,32 coincide
with the thermodynamically linked
residues,28,32 and second as Lee and
his colleagues31,32 have pointed out,
Ranganathan’s result28,32 derives from a
large number of PDZ domains; that is, it
is a characteristic of the family. Com-
munication pathways observed for a
family represent pathways shared by
the majority of PDZ domains; individual
PDZ domains may vary.
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Multiple pathways, efficient
response and the density of corres-
ponding interactions. Signal trans-
mission rarely occurs solely between
two specific binding sites. Consider the
following: (i) only two specific molecules
bind; however, external conditions
change; (ii) disease-related mutations
occur; (iii) there are more than two bind-
ing sites, thus complex cross-talk;
(iv) multiple modification sites; (v) some
receptors recognize many substrates, like
the kinase which recognizes up to
hundreds of phosphorylation sites. At the
same time there is an order of magnitude
more of potential phosphorylation sites
not being recognized by a specific kinase;39
(vi) dynamically co-regulated proteins
responsible for complex condition-
dependent regulation.40 Finally, binding
sites may be shared by different proteins.41
In allostery, as in folding, a single pathway
is unlikely to capture all sites and
conditions; at the same time, the converse
is also unlikely: not all pathways are
equally likely. A more realistic scenario is
a preferred pathway under given conditions.
Allostery is a purely
thermodynamic phenomenon
Two components are responsible for the
behavior of the system: enthalpy and
entropy. A binding event leads to loss
of freedom of motion of the binding
partners, including their internal
motions; thus it is entropy-unfavorable.
On the other hand, the added inter-
actions are enthalpy-favorable. The con-
tributions of the two terms are not
independent: during binding the inter-
actions get increasingly tighter (enthalpy-
favorable); at the same time, this process
is accompanied by loss of degrees of
freedom, thus the system increasingly
becomes entropy-unfavorable. The con-
verse also holds: loosening the inter-
actions decreases the enthalpy (i.e. it is
enthalpy-unfavorable); however, the
concomitantly increased mobility is
entropy-favorable. Allostery involves
(at least) two binding events; that of the
eﬀector and of the substrate. The eﬀector
binding can increase or decrease the
aﬃnity of the substrate: if it increases
the aﬃnity of the substrate it is said to be
positive cooperativity; if it decreases
the aﬃnity it is negative cooperativity.
Positive cooperativity can be dominated
by enthalpy or entropy. Enthalpy-
dominated positive cooperativity is driven
by the favorable tightening of the inter-
actions, with some entropy penalty
caused by the disorder to order events
at the substrate binding site; that is, part
of the entropy penalty for the binding
of the substrate is already pre-paid.
Enthalpy-dominated positive coopera-
tivity will present a conformational
change at the substrate binding site. In
entropy-dominated positive cooperativity,
the overall entropy cost of the two
binding events is lower than their sum.
Entropy-dominated positive coopera-
tivity can occur with or without con-
formational change.Negative cooperativity
is typically governed by unfavorable
entropy. Binding of the eﬀector leads to
an order to disorder event at the substrate
binding site; thus higher entropy cost.
Negative cooperativity is accompanied by
a conformational change. Cooperativity
is non-independent; that is, the overall
behavior of the system is not the sum of
its components.
The classification scheme with
examples
Classification scheme
Classiﬁcation schemes rest on deﬁni-
tions. Since the new view states that
absence of a change in shape does not
imply there is no allostery, we deﬁne
allostery as a change in the protein
activity in cellular pathways, for
example, signaling; viral entry; gene
regulation; enzymatic reactions. We
focus on function: we do not consider
conformational allostery-related changes
through agents unrelated to function.
The classiﬁcation considers the following
properties:
(i) Whether there is conformational
change at the substrate site.
(ii) Does the eﬀector perturbation lead
to positive (or negative) cooperativity of
the substrate binding?
(iii) Is the allosteric eﬀect enthalpy- or
entropy-driven?
(iv) Does the functional site coincide
with the substrate site? For the ﬁrst,
classiﬁcation is inferred visually; for the
second and fourth properties, biochemical
tests can provide answers; for the third, in
some cases it is straightforward; allosteric
eﬀects without a conformational change
are entropy-dominated; large conforma-
tional change is generally enthalpy-
dominated and disorder-to-order events
entropy-dominated. For others, calori-
metry determines thermodynamic factor
domination.
(v) Whether phosphorylation is
involved and if so in what functional
capacity? Phosphates play key roles in
signal transduction.
(vi) The oligomeric state, e.g. a pre-
formed dimer (example 4 below) or
separated monomers associating to form
a dimer (example 2). If it is an oligomer,
allostery may be concerted (e.g. in the
GroEL, or example 3) or not concerted
(example 8).
Fig. 1 implicitly provides all classiﬁca-
tion descriptors. Table 1 summarizes the
examples in these terms. Examples are
detailed in Fig. 2–4.
To clarify this scheme, let us consider
some scenarios. (i) Conformational
change. If we exclude here allosteric cases
governed by enthalpy and entropy, a
population shift accompanied by con-
formational change could be dominated
either by enthalpy or by entropy. On the
other hand, allosteric free energy change
without a conformational change is
dominated solely by entropy. (ii)
Cooperativity. In the case of enthalpy-
dominated allosteric eﬀect, the unfavorable
active site conformation becomes
substrate-favorable; thus, positive
cooperativity. The opposite holds for
negative cooperativity. For entropy-
dominated conformational change,
consider eﬀector binding making a dis-
ordered substrate binding site become
(partially) ordered. This is positive
cooperativity with pre-paid entropy loss.
(iii) Cooperativity and (absence of) con-
formational change. In the case of
allostery without conformational change,
there is an extra, non-additive entropy
loss due to substrate binding. This is
negative cooperativity with unfavorable
extra entropy loss due to enhanced
rigidiﬁcation. (iv) Phosphorylation. This
can lead to changes in protein activity
either via direct interference, where the
phosphate blocks the substrate binding
site; through formation of binding sites;
or the most common case, by a con-
formational change, acting as an
allosteric eﬀector via conformational
perturbation.42
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Example 1. Substrate (trimer)
dissociation: the seven-helix
receptors family (Fig. 2)
The seven-helix receptors family is topo-
logically similar to bacteriorhodopsin.
The N-terminal is outside the cell; the
C-terminal inside the cell. Ligands bind
to extracellular pockets. Small ligand
examples include 11-cis retinal which is
a light absorbing pigment; neurotrans-
mitters such as norepinephrine; drugs
and peptide hormones; small ligands like
glutamate and calcium; large ligands
including pituitary glycoprotein hormones
binding to the N-terminal domain. In
some cases, the N-terminal is cleaved
by interacting enzymes (e.g. thrombin);
the remaining N-terminal folds back,
mimicking ligand binding. Ligand bind-
ing drives a conformational change
through the transmembrane helices from
a resting to an activated state. The trans-
mitted signal leads to a conformational
change of the intracellular loops, creating a
binding site for a target trimeric G-protein.
The trimeric G-protein in its inactive
GDP-Gabg state with the Ga and Gg
anchored in the bilayer now catalyzes an
exchange of GTP to GDP on Ga.42 This
exchange is accompanied by dissociation
(thus negative cooperativity) of the now
active Ga and Gbg. While no thermo-
dynamic data are available, it appears to
be enthalpy-dominated.
Downstream eﬀector proteins amplify
the catalytic cascade, producing cAMP,
which activates protein kinase A (PKA)
via RII dissociation. PKA phosphorylates
phosphorylase kinases (PK). Phospho-
rylated calmodulin-phosphorylase binds
Ca2+ which now phosphorylates and acti-
vates phosphorylases. The phosphorylase
catalyzes the conversion of glycogen to
glucose-6-phosphate. Thus, the mechanism
of the seven-helix receptors family can be
classiﬁed as conformational change, negative
cooperativity, enthalpy-dominated (Table 1).
Fig. 1 Simpliﬁed diagrams illustrating the scheme of classiﬁcation of allosteric mechanisms. The scheme uses six descriptors to describe an
allosteric reaction: (1) the type of perturbation event at the allosteric site; (2) the extent of conformational change at the substrate site; (3) the
dominant thermodynamic factor; (4) the type of allosteric cooperativity; (5) the location of functional site (is it coincident with the substrate site?),
and (6) the functional oligomeric state in action. To facilitate module design in the representation, the core of an allosteric monomer is represented
by a triangle. Each triangle edge is occupied by one of three sites: the allosteric site, the substrate site, and the functional site. Fig. 1A depicts
a typical allosteric case in which the perturbation by an eﬀector binding at the allosteric site causes a minor conformational change at the substrate
site. The shape changes from circle (Oﬀ state) to triangle (On state) via multiple propagation pathways. The absence of an attached module to
the third edge of the core triangle indicates that in this case the substrate site is also the functional location of the monomeric protein. The
positive binding cooperativity is implied in Fig. 1A since no substrate is attached in the Oﬀ state. This is an enthalpy-driven allosteric regulation in
that the unfavorable substrate binding (Oﬀ state) becomes favorable (On state) due to an eﬀector binding at the allosteric site (Fig. 1B).
In this simpliﬁed modular scheme, a representation of a particular allosteric mechanism is just a combination of various stimuli at the allosteric
site (depicted in Fig. 1C) and of conformational changes at the substrate site (illustrated in Fig. 1D). A stimulus is an event that directly
inﬂuences protein function. The numbers in parentheses provide a visual guide corresponding to the six descriptors of the classiﬁcation
scheme.
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Example 2. Dimerization: epidermal
growth factor (EGF), or its
HER2/ErbB2 homolog (Fig. 3)
Polypeptide growth factors such as the
epidermal growth factor (EGF), or its
HER2/ErbB2 homolog, can bind to
plasma membrane receptors with cyto-
plasmic protein kinase activity such as
receptor tyrosine kinases. Binding can be
mediated by several common domains,
e.g. immunoglobulin, ﬁbronectin III and
cadhedrin; or b-helical and cysteine-rich
domains,42 permitting a range of favor-
able peptide binding. Extracellular EGF
binding induces a large conformational
change, exposing a binding site thus lead-
ing to extracellular domain association.
The conformational change propagates
through the membrane via a single trans-
membrane helix inducing intracellular
dimerization of the two cytoplasmic
kinase domains (positive cooperativity;
intracellular functional site not at the
extracellular substrate binding site).
While no thermodynamic data are avail-
able, it appears to be enthalpy-dominated.
The dimerized domains transphos-
phorylate each other’s tyrosines on the
kinase domains, initiating cascading
events. Phosphorylation leads to
conformational change, creating phos-
photyrosine binding sites for down-
stream SH2 and PTB domains. The
mechanism of the epidermal growth
factor (EGF), or its HER2/ErbB2 homo-
log can be classiﬁed as conformational
change, positive cooperativity, enthalpy-
dominated; functional site not at the sub-
strate site (Table 1).
Example 3. Tightening dimeric
interactions and association:
cytokine binding (Fig. 4)
Cytokines are hormones and growth
factors, regulating diverse cellular pro-
cesses such as mammalian growth and
development; proliferation and diﬀeren-
tiation and blood cells; and the immune
system. Cytokine receptors are pre-
formed homo- or heterodimers, all con-
taining two extracellular ﬁbronectin III
domains to which the cytokine binds.
Cytokine binding leads to a conforma-
tional change in the ﬁbronectin domains
propagating via the dimeric trans-
membrane helices. The consequent con-
formational change at the intracellular
domain-dimers draws them closer (inter-
face tightening at the substrate site) and
reorients them such that the two bound
tyrosine kinases get into proximity (asso-
ciation, positive cooperativity, functional
site not at the substrate site) allowing
them to transactivate each other by
trans-phosphorylation.42 Again, while
no thermodynamic data are available, it
appears to be enthalpy-dominated. STAT
transcription factor SH2 domain binds
to the receptor phosphotyrosine, facili-
tating STAT phosphorylation. STAT
subsequently dissociates, dimerizes and
enters the nucleus, activating gene
expression. The mechanism of the cyto-
kine binding can be classiﬁed as confor-
mational change, positive cooperativity,
enthalpy-driven; functional site not at the
substrate site (Table 1).
Example 4. Ternary complex
formation: Notch receptors
Notch receptors regulate cell fate, and are
key factors in cellular diﬀerentiation,
proliferation, apoptosis and stem cell
renewal.42,43 Notch receptors consist of
extracellular EGF-like domains and
leucine-rich repeats, a transmembrane
segment and intracellular ankyrin repeats.
Transmembrane protein DSL (Delta
Serrate Lag-2) activates the Notch recep-
tor of neighboring cells, freeing intra-
cellular domains (NotchIC) which move
back to the nucleus. Transcription factor
CSL is bound to DNA. NotchIC RAM
domain binds to CSL’s beta-trefoil
domain (BTD) triggering conformational
change in CSL’s N-terminal domain
(NTD). As a result, a binding site for
co-activator Mastermind is formed.
NotchIC ankyrin domain (ANK) then
Table 1 A summary of the six allosteric descriptors for the ten functional examples given in the text
1. Perturbation event at
the allosteric site
2. Extent of
conformational
change at the
substrate site
3. Dominant
thermodynamic
factor
4. Allosteric
cooperativity
5. Location of
functional site
6. Functional
oligomer status
in action
Example 1 Binding (ligands to
extracellular pockets)
Minor change Enthalpy-driven Negative At the substrate
site
Hetero-oligomer
Example 2 Binding (extracellular
EGF binding)
Domain-
movement
Enthalpy-driven Positive Not at the
substrate site
Monomeric
allostery
followed by
dimerization
Example 3 Cytokine binding Domain-
movement
Enthalpy-driven Positive At the substrate
site
Concerted
homo-dimer
Example 4 Binding (NotchIC
RAM domain to CSL’s
beta-trefoil domain)
Minor change Enthalpy-driven Positive At the substrate
site
Hetero-oligomer
Example 5 Binding (gp120 to CD4) Large change Enthalpy-driven Positive At the substrate
site
Monomer
Example 6 Binding (c-AMP to
CBD:b)
Large change Enthalpy-driven Positive At the substrate
site
Monomer
Example 7 Binding (Spz molecules
to Toll ectodomain)
Large change Enthalpy-driven Positive Not at the
substrate site
Concerted
Homo-dimer
Example 8 Binding (tryptophan to
TRAP)
Minor change Entropy-driven Positive At the substrate
site
Non-concerted
homo-oligomer
Example 9 Binding (cAMP to
CAP)
No change Entropy-driven Negative At the substrate
site
Homo-dimer
Example 10 Binding (Ffw7/Sel10 to
the phosphorylated site)
Minor change Enthalpy-driven Negative At the substrate
site
Hetero-oligomer
This journal is c The Royal Society of Chemistry 2009 Mol. BioSyst., 2009, 5, 207–216 | 211
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
Ja
nu
ar
y 
20
09
. D
ow
nl
oa
de
d 
on
 2
8/
04
/2
01
4 
11
:2
1:
28
. 
View Article Online
interacts with the CSL’s C-terminal
domain (CTD), creating an additional
Mastermind interaction site. Thus,
RAM’s binding to BTD increases the
eﬀective local concentration of ANK.
Mastermind’s binding (positive coopera-
tivity) completes the enthalpy-dominated
ternary complex formation, activating
transcription initiation. The Notch recep-
tor mechanism can thus be classiﬁed as
conformational change, positive coopera-
tivity, enthalpy-driven (Table 1).
Example 5. Ternary complex
formation: HIV-1 gp160
HIV-1 gp160 cleavage leads to envelope
proteins gp120 and gp41. gp120 binds to
CD4, a T-cell surface glycoprotein.
Binding leads to large conformational
change in gp120, exposing a binding site
and promoting co-receptor CCR5 or
CXCR4 binding (positive cooperativity).
The scorpion-toxin CD4-mimic, simi-
larly elicits a conformational change in
gp120.44 Thermodynamic data indicate
an enthalpy-driven process. The gp120
co-receptor interaction results in large
conformational changes in gp41, expos-
ing a heptad repeat region and the
leucine/isoleucine zipper region, assisting
in gp41 relocation from the gp120–gp41
interior to host membrane proximity and
subsequent viral nucleoprotein entry,
initiating the infection cycle.45 We
classify the mechanism of the HIV-1
gp160 as conformational change, positive
cooperativity, enthalpy-driven (Table 1).
Example 6. Salt-bridge cluster
weakening and competing isomers:
the cAMP-activated exchange
protein
cAMP-activated exchange protein
(EPAC) is a key ancient second messenger
receptor in mammals. cAMP activates the
guanine nucleotide-exchange factors in
the small GTPases Rap1 and Rap2. A
salt bridge cluster commonly called ionic
latch (IL) exists between the catalytic core
and the cAMP binding domain (CBD)
helices a1/a2. In the IL-stabilized closed
topology of the inactive state, the regula-
tory moiety occludes access to the cata-
lytic domain. CBD:b (covalently bound
to the Disheveled-Egl-10-Pleckstrin
domain and to Ras Exchange Motif via
the a6 hinge helix) interacts with the
N-terminal helical bundle (NTHB) which
interacts with the CDC25 homology
domain via these salt bridges. cAMP
binding to CBD:b leads to a6 hinge rota-
tion and equilibrium shift toward the
open state. Recent chemical shift
mapping unraveled the likely allosteric
mechanism: cAMP binding weakens the
IL although no signiﬁcant perturbation is
observed.46 The weakened salt bridges
facilitate a6 swiveling motions, allowing
Rap1 and Rap2 binding (positive coopera-
tivity). These GTPases control critical
signaling pathways, including insulin
secretion and cell adhesion. The authors
argue that salt bridge weakening is due
to increased entropic cost from the
NHTB enhanced dynamics (without
conformational change) following cAMP
binding. Alternatively, we propose that
this is an enthalpy-driven (conformational
change) allostery, where the perturbation
originating from cAMP binding pro-
pagates, leading to two competing states:
salt bridges-favored state and a compet-
ing Rap-bound state. The ﬂuctuations
between these two isomers lead to salt
bridge weakening. Thus, in Table 1,
cAMP-activated exchange protein is
classiﬁed as conformational change, posi-
tive cooperativity, enthalpy-driven.
Example 7. Two ligand two receptor
monomer (2 : 2) complex formation:
the Toll and Toll-like receptors
Toll and Toll-like receptors (TLR),
essential for immunity are activated by
microbial pathogen-derived ligands
which bind the extracellular Toll ecto-
domain. Drosophila Gram-positive
bacteria-derived peptidoglycan stimulates
Spa¨tzle (Spz) synthesis, which binds to the
ectodomain, initiating signal transduction.
This domain consists of leucine-rich re-
peats (LRR) arranged as an N- and C-
termini capped solenoid. There are two
linker-connected terminal capped LRRs.
A single transmembrane segment connects
the ectodomain to an intracellular TIR
signaling module. Previously it was
believed that Toll activation involved a
single Spz cross-linking two Toll ectodo-
mains; however, recent cryo-EM and mass
spectrometry data show that two Spz
molecules bind to the N-termini of two
Toll ectodomains triggering a more tightly
curved ectodomain conformation (confor-
mational change) and dimer formation
(positive cooperativity, enthalpy-driven)
through interaction at the N-terminal
and the juxtamembrane sequences.47
Hence, this family provides an example
Fig. 2 Two simpliﬁed diagrams to illustrate the allosteric mechanisms of the exchange of GTP
to GDP in example 1 in the text. In Fig. 2A, an extracelluar ligand binding at the N-terminal
domain of the receptor (the allosteric site) causes a conformational change at the GDP binding
site (the substrate site) leading to the release of GDP. This is a hetero-oligomer system with
negative binding cooperativity driven mainly by enthalpy. The empty GDP binding site then
becomes an allosteric site for GTP binding in Fig. 2B. The GTP binding event causes the
dissociation of trimeric G-protein from the seven-helix receptor. If we retain the classiﬁcation
scheme with the seven-helix receptor as the core protein, the substrate will be the entire trimetric
G-protein and the allosteric site is located inside the substrate; however, if we view the G-protein
as the core protein, then the GTP binding is a negative cooperative binding leading to
dissociation of the substrate, now the seven-helix receptor.
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of a classiﬁcation of allostery with confor-
mational change, positive cooperativity,
enthalpy-driven (Table 1).
Example 8. Symmetric multi-subunit
ring: the trp RNA binding
attenuation protein
trp RNA binding attenuation protein
(TRAP) is a symmetric, 11-mer ring,
involved in the regulation of intracellular
levels of tryptophan in some bacteria.48
TRAP–tryptophan complex binds to trp
mRNA leader sequence; consequent
hairpin formation prevents downstream
transcription. Tryptophan-unbound
TRAP cannot bind RNA. Bacillus
stearothemophilus TRAPste NMR data
indicate that in the absence of Trp, the
RNA binding site is disordered;49 Trp
binding promotes disorder to order con-
formational change, prepaying the entro-
pic cost. Trp binding to Bacillus subtilus
TRAP (TRAPsub) is non-cooperative;
thus, function does not require inter-
subunit cooperativity. On the other
hand, TRAPste presents weak positive
cooperativity. While tryptophan-free
TRAPste is unable to bind RNA, binding
of one Trp to one of the eleven TRAP
monomers is suﬃcient for high aﬃnity
RNA binding. Isothermal titration
calorimetry explains the diﬀerence bet-
ween the behavior of the two TRAPs:
unlike TRAPste, in TRAPsub the bindings
are non-cooperate events; however, a
single TRAPsub (Ile to Leu) mutation
leads to inter-subunit Trp binding coop-
erativity. The single mutation is suﬃcient
for the weak positive cooperativitivity,
presumably enthalpy-dominated. Hence,
in Table 1 we classify this protein as
conformational change, (weak) positive
cooperativity, enthalpy-driven.
Example 9. Homodimer: the CAP
example
Catabolite activator protein (CAP) con-
trols over 100 genes. CAP is a homo-
dimeric transcriptional activator. Each
subunit has an N-terminal ligand
(cAMP) binding domain and C-terminal
DNA binding domain. cAMP binding to
CAP increases its aﬃnity to DNA. CAP
unwinds the double helix, allowing RNA
polymerase binding and transcription.
The two cAMPs bind CAP with negative
cooperativity: despite the large spatial
separation between the cAMP binding
pockets (24 A˚ between the cAMP’s phos-
phates), binding of one cAMP reduces
the binding aﬃnity of the other by 2
orders of magnitude. NMR studies of
N-terminal truncated CAP domains
(CAPN) indicated that binding of the
ﬁrst cAMP does not lead to an observable
conformational change in the binding site
of the second cAMP; thus it is entropy-
controlled. Popovych et al. proposed a
mechanism where the ﬁrst cAMP bind-
ing increases the entropy, forcing the
second cAMP binding to pay higher
cost.23 In the absence of cAMP, CAPN,
including cAMP binding sites, is highly
ﬂexible as shown by hydrogen exchange
rates. Binding of the ﬁrst cAMP has little
eﬀect on the ps–ns time scales ﬂexibility
but it enhances the slow motions (ms–ms).
This aﬀects the conformation of the
liganded but not the unliganded subunit.
The second cAMP binding suppresses the
fast and the slow motions, thus there is a
lower favorable entropy change as com-
pared to the ﬁrst cAMP binding, and
negative cooperativity. Alternatively,3 the
ﬁrst cAMP binding increases the overall
rigidiﬁcation; being symmetric occur-
rences, the second cAMP binding simi-
larly increases the overall rigidiﬁcation.
Fig. 3 Simpliﬁed diagrams to illustrate the allosteric mechanism of dimerization in example 2.
The EGF binding event causes a large-scale, domain-movement conformational change at the
substrate site, which in turn facilitates the dimerization. The extracellular dimerization process
leads to a contact between the two intracellular functional sites, the cytoplasmic kinase domains.
This represents a homodimer system where the substrate site is not at the functional site.
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Propagation of the rigidiﬁcations and
path-meeting create extra unfavorable en-
tropy terms.50 This is an example of no
conformational change, negative coopera-
tivity, entropy-driven (Table 1).
Example 10. Ternary complex
dissociation: the CSL/NotchIC/
Mastermind organization
CSL, associates in the ternary com-
plex with Notch intracellular (NotchIC)
domains RAM, and ANK and Master-
mind (see example 4).42,43 CDK8
phosphorylates the ANK domain,
creating the Ffw7/Sel10 eﬀector binding
site. While no structural data are
available, no conformational change is
expected in phosphorylation-binding site
formation. Ffw7/Sel10 binding to the
phosphorylated site can compete for
space with the CSL/NotchIC/Mastermind
organization to avoid direct interference.
The outcome is NotchIC and Master-
mind dissociation with subsequent
degradation by the E2 ubiquitin ligase.
While no data are available, we can
expect that eﬀector binding leads to an
enthalpy-driven conformational change. Dis-
sociation implies negative cooperativity.
Subsequent transcriptional co-repressor
binding and histone deacetylase recruit-
ment lead to repression. This is an
example where phosphorylation creates a
binding site, with conformational change,
negative cooperativity, enthalpy-driven
(Table 1).
Discussion and conclusions
Classiﬁcation assists not only in organi-
zing information but also in making
sense of observations: what are the
diﬀerences between plants and animals;
invertebrates and vertebrates; between
cold and warm blooded animals; bet-
ween mammals, birds, reptiles, ﬁsh, and
amphibians; between classes of protein
structures; drugs; types of interactions
and chemical reactions. Sorting objects
into distinct categories organizes the
information, revealing patterns and
relationships, and consequently provides
insight. While the importance of classiﬁ-
cation is clear, how to classify and into
which categories is less obvious. Relevant
questions are (i) which properties to use;
(ii) is the range of available cases suﬃ-
cient; (iii) should categories lumped
together require splitting; (iv) if we had
started from diﬀerent (to be discovered)
examples, would the classiﬁcation
scheme be similar? A relevant classiﬁca-
tion scheme should relate to function and
eventually must correlate with quantities
allowing automated classiﬁcation based
on a set of analytical or empirical com-
ponents. With these caveats in mind, we
believe that the increase in the number of
observed allostery cases, their breadth,
the recent insight into allostery types and
mechanisms, and their impact on cellular
functions permits a ﬁrst step in a classi-
ﬁcation scheme, which we expect to assist
in organization, comprehension and in
allosteric drug discovery.
Here we provide a comprehensive
description and a framework for classiﬁ-
cation of allosteric mechanisms with
some examples abstracted from a range
of cellular processes. This was made
possible by ﬁrst obtaining a uniﬁed
Fig. 4 Simpliﬁed diagrams to illustrate the allosteric mechanisms of the pre-formed dimer in
example 3. Eﬀector binding at the allosteric sites causes a large-scale conformational change at
the substrate site, which brings the two separated substrates (the two triangles) in close contact
to each other. This is a concerted homodimer system: the two substrate sites become the
functional site when they are in close contact.
214 | Mol. BioSyst., 2009, 5, 207–216 This journal is c The Royal Society of Chemistry 2009
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
Ja
nu
ar
y 
20
09
. D
ow
nl
oa
de
d 
on
 2
8/
04
/2
01
4 
11
:2
1:
28
. 
View Article Online
mechanistic view of allostery. The classi-
ﬁcation is based on several properties:
presence/absence of conformational
change; cooperativity type; driving
thermodynamic terms; whether the sub-
strate binding site and the functional site
coincide; and role of phosphorylation
(if present). We observed numerous
examples of disorder-to-order conforma-
tional change with the ﬁrst binding event
prepaying the entropy cost. These com-
mon allostery cases display positive
cooperativity and are lumped into the
same classiﬁcation bin. At the same time,
order-to-disorder cases entail high
entropy cost and fall into the negative
cooperativity with conformational change
rubric.
Mutations were not treated here. Yet,
mutations can lead to disease via allos-
teric eﬀects. Consider for example the
seven-helix transmembrane receptor.
According to Pollard et al.42 over 600
mutations in more than 30 receptors of
this family have been linked to disease.
If the mutations occur at the ligand
or the trimeric G-protein binding sites
(including binding site truncation events,
as for example at the N-terminal) these
are not allosteric mutations. On the other
hand, mutations occurring elsewhere and
aﬀecting binding are allosteric events.
Mutations can lead to eﬀector unfavo-
rable N-terminal conformations; under
such circumstances, there is no con-
formational change of the intracellular
loops, thus no activation of the trimeric
G-protein, which will remain in the
receptor-bound state. These mutations
lead to loss of function. In contrast,
mutations leading to a conformational
change at the G-protein binding site
constitutively activate the reaction
regardless of whether a ligand is bound.
Mutations in tyrosine kinases can lead to
disease. If these mutations are away
from the binding sites, similar allosteric
mechanisms may operate.51
Eventually, a systematic compilation
and organization of available allostery
cases, encompassing a range of eﬀectors
and environments within the functional
signaling transduction context would
be invaluable. Allostery is the vehicle
through which function is exerted. Classi-
fying allosteric cases transforms pheno-
menological descriptions to molecular
mechanisms. To cite two examples, con-
sider the text-book description of a GTP
to GDP exchange in the seven-helix
receptors case:42 here a classiﬁcation
scheme clariﬁes how the function is
performed in this step of the catalytic
phosphorylation signaling cascade.
Classiﬁcation indicates that two allosteric
steps are involved (Fig. 2; example 1)
where a substrate site initially occupied
by GDP becomes an allosteric site which,
via negative cooperativity leads to the
dissociation of the substrate, now the
seven-helix receptor. Classifying the recep-
tor tyrosine kinase case (example 2) clari-
ﬁes that the functional site diﬀers from
the substrate binding site, a key mecha-
nistic component which was unclear
before (Fig. 3). Text books describe series
of events; not mechanisms. They cite the
event and its consequences: a certain gene
knock-out will lead to a certain loss of
function. Yet, in disease our goal is to be
able to trace back to a particular signal-
ing check-point; to identify the source of
the functional loss. Further, a disease-
related mutation does not have to be in
the substrate or the functional sites; but
it may block signal propagation.
Classiﬁcation has proven immensely
important in science. Here we provide
the ﬁrst classiﬁcation framework for
allostery based on six properties; this
implies that a change in any of the six
properties would aﬀect function. A key
question is which property would aﬀect it
the most. Hence, if the mechanism
involves dimerization (example 2; pro-
perty 6, Table 1) concentration and bind-
ing constants are crucial. If the substrate
binding site diﬀers from the functional
site (example 3; property 5 Table 1)
a mutation in the functional site can
abolish substrate binding. If there is a
hinge bending conformational change
(examples 2 and 3; property 2) a muta-
tion altering its extent can lead to
functional loss; this property relates to
propagation pathways and to dominant
thermodynamic factors (property 3); muta-
tions aﬀecting perturbation (property 1)
can have a similar eﬀect to allosteric
cooperativity (property 4): no perturba-
tion, no cooperativity. Additional de-
scriptors would surely be incorporated
as the range of cases broadens. Clearly,
ﬁguring out allosteric mechanisms is
crucial for the comprehension of
how function is performed in the cell.
Using a classiﬁcation scheme along the
lines proposed here should complement
text-book descriptions; it should assist in
the understanding of how the function is
performed on the single molecule level
within the framework of its complex cel-
lular environment.
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